# Georgiamune

Source: https://onco.cc/companies/georgiamune/  
OnCo record `georgiamune` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Georgiamune is a United States-based biotechnology company running 2 late-stage cancer trials of GIM122 and GIM-531 in melanoma.

## Summary

Georgiamune, based in Gaithersburg, the United States, is a biotechnology company. Georgiamune develops immunotherapies that reprogram immune signalling pathways to rebalance immune system components, for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GIM122 and GIM-531 in melanoma. The largest, NCT06425926 (Safety and Tolerability Study of GIM-531 in Advanced Solid Tumours), plans to enrol 117 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Georgiamune Inc
- Tags: ctgov-sponsor
- HQ: Gaithersburg
- Type: biotech
- Website: https://www.georgiamune.com

## Sources

- Official website: https://www.georgiamune.com
- ClinicalTrials.gov: trials led by Georgiamune: https://clinicaltrials.gov/search?lead=Georgiamune%20Inc

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies](https://onco.cc/trials/nct06028074/), [Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors](https://onco.cc/trials/nct06425926/)

---
JSON: https://onco.cc/api/v1/entities/georgiamune.json